Paste your Google Webmaster Tools verification code here
The intensifying eye of FDA on the Indian units of many pharmaceutical and biotech companies has raised many eyebrows on the issue striving to figure out who is correct and who is not. The current issue talks about the same,analyzing and viewing the point of views of both the parties.
Read tete-a-tete with a start-up Theramyt, SRM University in the campus watch and Biorizon
Also read in the issue
While Indian Pharma industries are ridden with worries about the escalating examination and inspection by FDA, the regulator has a justification that it is the American public health which is at stake. Not one, mot two, but approximately eighteen different drug exporters in India have received warning letters in the past one year…
2014 Powered By Wordpress, Goodnews Theme By Momizat Team